Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Sep 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Rising Leverage ⢠Persistent Losses ADPT has ample liquidity but worsening leverage, persistent losses, negative cash flow, and a premium valuation that heightens financing and execution risk.
Price Behavior
Key Price Behavior Insights: ⢠Failed late-August rally ⢠Weak support test ⢠Bearish near-term trend Support Level: $24.20â$24.30 Resistance Level: $24.90â$25.20 ADPT is testing weak $24.20â$24.30 support after a failed rally, with a move above $25.20 needed to improve momentum and a break below $24.20 signaling further downside.
Sentiment & News
Key News Insights: ⢠Major stake cuts ⢠Healthcare conference ⢠AI startup funding Adaptive faces notable institutional selling pressure, partly offset by investor-conference visibility and a co-founder's AI startup funding.
AI Summary
ADPT has shifted from a cash-rich platform-biotech story to a leveraged MRD execution bet: investors should demand evidence that high-margin MRD growth delivers sustained operating cash flow before adding exposure, as elevated debt, convertible dilution risk, and a premium valuation leave little room for misses.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |